124 related articles for article (PubMed ID: 6783296)
41. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
42. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
43. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
44. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Lawson D; Moore M; Smalley R
Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
[TBL] [Abstract][Full Text] [Related]
45. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
46. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer.
Akerley W; Glantz M; Choy H
Semin Oncol; 1996 Oct; 23(5 Suppl 12):14-8. PubMed ID: 8941405
[TBL] [Abstract][Full Text] [Related]
47. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
48. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
49. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
50. Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Bolis G; D'Incalci M; Belloni C; Mangioni C
Cancer Treat Rep; 1979 Aug; 63(8):1375-7. PubMed ID: 113096
[TBL] [Abstract][Full Text] [Related]
51. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
52. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
53. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff RB; Casper ES; Magill GB; Young CW
Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
[TBL] [Abstract][Full Text] [Related]
56. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
[TBL] [Abstract][Full Text] [Related]
57. First-pass metabolism of pentamethylmelamine in the rat liver.
Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
[TBL] [Abstract][Full Text] [Related]
58. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
59. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
60. cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancer.
Lopez JA; Krikorian JG; Dias SF; Spiers AS; Finkel HE; Barnard DE
Gynecol Oncol; 1981 Feb; 11(1):64-7. PubMed ID: 6781990
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]